Abstract
Nanotechnology is an emerging multidisciplinary field that offers unprecedented access to living cells of target (i.e. cancer cells) and promises the state of the art in cancer detection and treatment. Development of nanocarriers that target cancer for diagnostics and therapy draws upon principles in the field of chemistry, medicine, physics, biology, and engineering. Given the zealous activity in the field as demonstrated by over 7000 published journal articles on the topic and given the promise of recent clinical results, nanocarrier-based approaches are anticipated to soon have a profound impact on cancer medicine and as a consecuence on human health. The versatility in size, material, and targeting agents of nanocarriers permits potential targeting for individual cancer cells. This chapter addresses nanocarriers spanning liposomes to polymeric nanoparticles, inorganic nanoparticles,polymers conjugates and dendrimers. The targeting approaches include conjugation of molecules such as receptor-specific ligands, antibodies and aptamers to the surface of the carrier. Targeting cancer with nanocarriers represent the next important milestone that is already impacts the lives of millions around the world. One such example, is of DaunoXome (Liposomal Daunorubicin) for Acute myeloid Leukemia (AML) treatment that shows an increased intratumor and intracellular levels of the drug, while normal tissue toxicity, including cardiotoxicity, may be reduced.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Fassas A, Anagnostopoulos A (2005) The use of liposomal daunorubicin (DaunoXome) in acute myeloid leukemia. Leuk Lymphoma 46(6):795–802
Ferrari M (2005) Cancer nanotechnology: opportunities and challenges. Nat Rev Cancer 5(3):161–171
Farokhzad OC et al (2006) Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proc Natl Acad Sci U S A 103(16):6315–6320
Peer D, Margalit R (2004) Loading mitomycin C inside long circulating hyaluronan targeted nano-liposomes increases its antitumor activity in three mice tumor models. Int J Cancer 108(5):780–789
Duncan R (2006) Polymer conjugates as anticancer nanomedicines. Nat Rev Cancer 6(9):688–701
Kukowska-Latallo JF et al (2005) Nanoparticle targeting of anticancer drug improves therapeutic response in animal model of human epithelial cancer. Cancer Res 65(12):5317–5324
Maeda H (2001) The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv Enzyme Regul 41:189–207
Maeda H, Sawa T, Konno T (2001) Mechanism of tumor-targeted delivery of macromolecular drugs, including the EPR effect in solid tumor and clinical overview of the prototype polymeric drug SMANCS. J Control Release 74(1–3):47–61
Lucas AT, Madden AJ, Zamboni WC (2015) Formulation and physiologic factors affecting the pharmacology of carrier-mediated anticancer agents. Expert Opin Drug Metab Toxicol 11(9):1419–1433
Antony AC (1992) The biological chemistry of folate receptors. Blood 79(11):2807–2820
Scomparin A et al (2015) A comparative study of folate receptor-targeted doxorubicin delivery systems: dosing regimens and therapeutic index. J Control Release 208:106–120
Quintana A et al (2002) Design and function of a dendrimer-based therapeutic nanodevice targeted to tumor cells through the folate receptor. Pharm Res 19(9):1310–1316
Benns JM, Mahato RI, Kim SW (2002) Optimization of factors influencing the transfection efficiency of folate-PEG-folate-graft-polyethylenimine. J Control Release 79(1–3):255–269
Leamon CP, Low PS (1991) Delivery of macromolecules into living cells: a method that exploits folate receptor endocytosis. Proc Natl Acad Sci U S A 88(13):5572–5576
Lee RJ, Low PS (1994) Delivery of liposomes into cultured KB cells via folate receptor-mediated endocytosis. J Biol Chem 269(5):3198–3204
Scomparin A et al (2011) Novel folated and non-folated pullulan bioconjugates for anticancer drug delivery. Eur J Pharm Sci 42(5):547–558
Prost AC et al (1998) Differential transferrin receptor density in human colorectal cancer: a potential probe for diagnosis and therapy. Int J Oncol 13(4):871–875
Iinuma H et al (2002) Intracellular targeting therapy of cisplatin-encapsulated transferrin-polyethylene glycol liposome on peritoneal dissemination of gastric cancer. Int J Cancer 99(1):130–137
Ishida O et al (2001) Liposomes bearing polyethyleneglycol-coupled transferrin with intracellular targeting property to the solid tumors in vivo. Pharm Res 18(7):1042–1048
Gijsens A et al (2002) Targeting of the photocytotoxic compound AlPcS4 to Hela cells by transferrin conjugated PEG-liposomes. Int J Cancer 101(1):78–85
Kolhatkar R, Lote A, Khambati H (2011) Active tumor targeting of nanomaterials using folic acid, transferrin and integrin receptors. Curr Drug Discov Technol 8(3):197–206
Yu B et al (2010) Receptor-targeted nanocarriers for therapeutic delivery to cancer. Mol Membr Biol 27(7):286–298
Cinci M et al (2015) Targeted delivery of siRNA using transferrin-coupled lipoplexes specifically sensitizes CD71 high expressing malignant cells to antibody-mediated complement attack. Target Oncol 10(3):405–413
Kuang Y et al (2013) T7 peptide-functionalized nanoparticles utilizing RNA interference for glioma dual targeting. Int J Pharm 454(1):11–20
Bartolazzi A et al (1994) Interaction between CD44 and hyaluronate is directly implicated in the regulation of tumor development. J Exp Med 180(1):53–66
Stamenkovic I, Aruffo A (1994) Hyaluronic acid receptors. Methods Enzymol 245:195–216
Zeng C et al (1998) Inhibition of tumor growth in vivo by hyaluronan oligomers. Int J Cancer 77(3):396–401
Thomas RG et al (2015) Paclitaxel loaded hyaluronic acid nanoparticles for targeted cancer therapy: in vitro and in vivo analysis. Int J Biol Macromol 72:510–518
Lesley J, Hyman R (1998) CD44 structure and function. Front Biosci 3:D616–D630
Sneath RJ, Mangham DC (1998) The normal structure and function of CD44 and its role in neoplasia. Mol Pathol 51:191–200
Cohen ZR et al (2015) Localized RNAi therapeutics of chemoresistant grade IV glioma using hyaluronan-grafted lipid-based nanoparticles. ACS Nano 9(2):1581–1591
Mizrahy S et al (2014) Tumor targeting profiling of hyaluronan-coated lipid based-nanoparticles. Nanoscale 6(7):3742–3752
Narayanan D, Jayakumar R, Chennazhi KP (2014) Versatile carboxymethyl chitin and chitosan nanomaterials: a review. Wiley Interdiscip Rev Nanomed Nanobiotechnol 6(6):574–598
Kawakami S et al (2000) Mannose receptor-mediated gene transfer into macrophages using novel mannosylated cationic liposomes. Gene Ther 7(4):292–299
Shan D et al (2015) RGD-conjugated solid lipid nanoparticles inhibit adhesion and invasion of alphavbeta 3 integrin-overexpressing breast cancer cells. Drug Deliv Transl Res 5(1):15–26
Wang K et al (2014) Tumor penetrability and anti-angiogenesis using iRGD-mediated delivery of doxorubicin-polymer conjugates. Biomaterials 35(30):8735–8747
Dagar S et al (2003) VIP grafted sterically stabilized liposomes for targeted imaging of breast cancer: in vivo studies. J Control Release 91(1–2):123–133
Dagar S et al (2001) VIP receptors as molecular targets of breast cancer: implications for targeted imaging and drug delivery. J Control Release 74(1–3):129–134
Dagar A et al (2012) VIP-targeted cytotoxic nanomedicine for breast cancer. Drug Deliv Transl Res 2(6):454–462
Guan YY et al (2014) Selective eradication of tumor vascular pericytes by peptide-conjugated nanoparticles for antiangiogenic therapy of melanoma lung metastasis. Biomaterials 35(9):3060–3070
Mei L et al (2014) Enhanced antitumor and anti-metastasis efficiency via combined treatment with CXCR4 antagonist and liposomal doxorubicin. J Control Release 196:324–331
Warenius HM et al (1981) Attempted targeting of a monoclonal-antibody in a human-tumor xenograft system. Eur J Cancer Clin Oncol 17(9):1009–1015
von Mehren M, Adams GP, Weiner LM (2003) Monoclonal antibody therapy for cancer. Annu Rev Med 54:343–369
Weiner LM, Adams GP (2000) New approaches to antibody therapy. Oncogene 19(53):6144–6151
James JS, Dubs G (1997) FDA approves new kind of lymphoma treatment. Food and Drug Administration. AIDS Treat News (No 284):2–3
Albanell J, Baselga J (1999) Trastuzumab, a humanized anti-HER2 monoclonal antibody, for the treatment of breast cancer. Drugs Today (Barc) 35(12):931–946
Zhou Y et al (2015) Combination therapy of prostate cancer with HPMA copolymer conjugates containing PI3K/mTOR inhibitor and docetaxel. Eur J Pharm Biopharm 89:107–115
Ferrara N (2005) VEGF as a therapeutic target in cancer. Oncology 69(Suppl 3):11–16
Ferrara N, Hillan KJ, Novotny W (2005) Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res Commun 333(2):328–335
Gerber HP, Ferrara N (2005) Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res 65(3):671–680
Gibson AD (2002) Phase III trial of a humanized anti-CD33 antibody (HuM195) in patients with relapsed or refractory acute myeloid leukemia. Clin Lymphoma 3(1):18–19
Javle M, Smyth EC, Chau I (2014) Ramucirumab: successfully targeting angiogenesis in gastric cancer. Clin Cancer Res 20(23):5875–5881
White RR, Sullenger BA, Rusconi CP (2000) Developing aptamers into therapeutics. J Clin Invest 106(8):929–934
Tuerk C, Gold L (1990) Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 249(4968):505–510
Ellington AD, Szostak JW (1990) In vitro selection of RNA molecules that bind specific ligands. Nature 346(6287):818–822
Blank M et al (2001) Systematic evolution of a DNA aptamer binding to rat brain tumor microvessels, selective targeting of endothelial regulatory protein pigpen. J Biol Chem 276(19):16464–16468
Morris KN et al (1998) High affinity ligands from in vitro selection: complex targets. Proc Natl Acad Sci U S A 95(6):2902–2907
Beigelman L et al (1995) Chemical modification of hammerhead ribozymes. Catalytic activity and nuclease resistance. J Biol Chem 270(43):25702–25708
Aurup H, Williams DM, Eckstein F (1992) 2′-Fluoro- and 2′-amino-2′-deoxynucleoside 5′-triphosphates as substrates for T7 RNA polymerase. Biochemistry 31(40):9636–9641
Pieken WA et al (1991) Kinetic characterization of ribonuclease-resistant 2′-modified hammerhead ribozymes. Science 253(5017):314–317
Eulberg D, Klussmann S (2003) Spiegelmers: biostable aptamers. Chembiochem 4(10):979–983
Wang DL et al (2014) Selection of DNA aptamers against epidermal growth factor receptor with high affinity and specificity. Biochem Biophys Res Commun 453(4):681–685
Farokhzad OC et al (2004) Nanoparticle-aptamer bioconjugates: a new approach for targeting prostate cancer cells. Cancer Res 64(21):7668–7672
Rosenberg JE et al (2014) A phase II trial of AS1411 (a novel nucleolin-targeted DNA aptamer) in metastatic renal cell carcinoma. Invest New Drugs 32(1):178–187
Gref R et al (1994) Biodegradable long-circulating polymeric nanospheres. Science 263(5153):1600–1603
Langer R, Peppes NA (2003) Advances in biomaterials, drug delivery, and bionanotechnology. AICHE J 49(12):2990–3006
Gref R et al (1997) Poly(ethylene glycol)-coated nanospheres: potential carriers for intravenous drug administration. Pharm Biotechnol 10:167–198
Santini JT Jr, Cima MJ, Langer R (1999) A controlled-release microchip. Nature 397(6717):335–338
Chertok B et al (2013) Drug delivery interfaces in the 21st century: from science fiction ideas to viable technologies. Mol Pharm 10(10):3531–3543
Langer R, Tirrell DA (2004) Designing materials for biology and medicine. Nature 428(6982):487–492
Brigger I et al (2004) Negative preclinical results with stealth nanospheres-encapsulated Doxorubicin in an orthotopic murine brain tumor model. J Control Release 100(1):29–40
Garcia-Carbonero R, Supko JG (2002) Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins. Clin Cancer Res 8(3):641–661
Khandare J, Minko T (2006) Polymer-drug conjugates: progress in polymeric prodrugs. Prog Polym Sci 31(4):359–397
Bangham AD, Horne RW (1964) Negative staining of phospholipids and their structural modification by surface-active agents as observed in the electron microscope. J Mol Biol 12:660–668
Bangham AD, Standish MM, Watkins JC (1965) Diffusion of univalent ions across the lamellae of swollen phospholipids. J Mol Biol 13(1):238–252
Horne RW, Bangham AD, Whittaker VP (1963) Negatively stained lipoprotein membranes. Nature 200:1340
Forssen EA, Ross ME (1994) Daunoxome® treatment of solid tumors: preclinical and clinical investigations. J Liposome Res 4(1):481–512
Chang HI, Yeh MK (2012) Clinical development of liposome-based drugs: formulation, characterization, and therapeutic efficacy. Int J Nanomedicine 7:49–60
Gabizon AA (2001) Stealth liposomes and tumor targeting: one step further in the quest for the magic bullet. Clin Cancer Res 7(2):223–225
Gabizon AA (2001) Pegylated liposomal doxorubicin: metamorphosis of an old drug into a new form of chemotherapy. Cancer Invest 19(4):424–436
Safra T et al (2000) Pegylated liposomal doxorubicin (doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2. Ann Oncol 11(8):1029–1033
Olson F et al (1979) Preparation of liposomes of defined size distribution by extrusion through polycarbonate membranes. Biochim Biophys Acta 557(1):9–23
Slingerland M, Guchelaar HJ, Gelderblom H (2012) Liposomal drug formulations in cancer therapy: 15 years along the road. Drug Discov Today 17(3–4):160–166
Torchilin VP (2005) Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov 4(2):145–160
Perche F, Torchilin VP (2013) Recent trends in multifunctional liposomal nanocarriers for enhanced tumor targeting. J Drug Deliv 2013:705265
Blume G et al (1993) Specific targeting with poly(ethylene glycol)-modified liposomes: coupling of homing devices to the ends of the polymeric chains combines effective target binding with long circulation times. Biochim Biophys Acta 1149(1):180–184
Allen TM, Mumbengegwi DR, Charrois GJ (2005) Anti-CD19-targeted liposomal doxorubicin improves the therapeutic efficacy in murine B-cell lymphoma and ameliorates the toxicity of liposomes with varying drug release rates. Clin Cancer Res 11(9):3567–3573
Park JW et al (2002) Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery. Clin Cancer Res 8(4):1172–1181
Gao J et al (2009) Tumor-targeted PE38KDEL delivery via PEGylated anti-HER2 immunoliposomes. Int J Pharm 374(1–2):145–152
Gabizon A et al (2010) Improved therapeutic activity of folate-targeted liposomal doxorubicin in folate receptor-expressing tumor models. Cancer Chemother Pharmacol 66(1):43–52
Eavarone DA, Yu X, Bellamkonda RV (2000) Targeted drug delivery to C6 glioma by transferrin-coupled liposomes. J Biomed Mater Res 51(1):10–14
Maruyama K (2011) Intracellular targeting delivery of liposomal drugs to solid tumors based on EPR effects. Adv Drug Deliv Rev 63(3):161–169
Jones RA (2004) Tough and smart. Nat Mater 3(4):209–210
Sawant RM et al (2006) “SMART” drug delivery systems: double-targeted pH-responsive pharmaceutical nanocarriers. Bioconjug Chem 17(4):943–949
Ghanbarzadeh S et al (2014) Improvement of the antiproliferative effect of rapamycin on tumor cell lines by poly (monomethylitaconate)-based pH-sensitive, plasma stable liposomes. Colloids Surf B Biointerfaces 115:323–330
Ducat E et al (2011) Nuclear delivery of a therapeutic peptide by long circulating pH-sensitive liposomes: benefits over classical vesicles. Int J Pharm 420(2):319–332
Mizrahy S et al (2011) Hyaluronan-coated nanoparticles: the influence of the molecular weight on CD44-hyaluronan interactions and on the immune response. J Control Release 156(2):231–238
Peer D et al (2007) Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol 2(12):751–760
Landesman-Milo D et al (2013) Hyaluronan grafted lipid-based nanoparticles as RNAi carriers for cancer cells. Cancer Lett 334(2):221–227
Peer D, Margalit R (2004) Tumor-targeted hyaluronan nanoliposomes increase the antitumor activity of liposomal Doxorubicin in syngeneic and human xenograft mouse tumor models. Neoplasia 6(4):343–353
Eliaz RE, Szoka FC Jr (2001) Liposome-encapsulated doxorubicin targeted to CD44: a strategy to kill CD44-overexpressing tumor cells. Cancer Res 61(6):2592–2601
Peer D et al (2008) Systemic leukocyte-directed siRNA delivery revealing cyclin D1 as an anti-inflammatory target. Science 319(5863):627–630
Kandra P, Kalangi HP (2015) Current understanding of synergistic interplay of chitosan nanoparticles and anticancer drugs: merits and challenges. Appl Microbiol Biotechnol 99(5):2055–2064
Sahu SK et al (2011) Hydrophobically modified carboxymethyl chitosan nanoparticles targeted delivery of paclitaxel. J Drug Target 19(2):104–113
Yang R et al (2009) Lung-specific delivery of paclitaxel by chitosan-modified PLGA nanoparticles via transient formation of microaggregates. J Pharm Sci 98(3):970–984
Malhotra M et al (2013) Systemic siRNA delivery via peptide-tagged polymeric nanoparticles, targeting PLK1 gene in a mouse xenograft model of colorectal cancer. Int J Biomater 2013:252531
Wang X et al (2014) Delivery of platinum(IV) drug to subcutaneous tumor and lung metastasis using bradykinin-potentiating peptide-decorated chitosan nanoparticles. Biomaterials 35(24):6439–6453
Marty JJ, Oppenheim RC, Speiser P (1978) Nanoparticles—new colloidal drug delivery system. Pharm Acta Helv 53(1):17–23
Alonso MJ et al (1994) Biodegradable microspheres as controlled-release tetanus toxoid delivery systems. Vaccine 12(4):299–306
Qaddoumi MG et al (2002) Molecular mechanisms mediating the cEdocytosis of biodegradable PLGA nanoparticles in rabbit conjunctival epithelial cell layers. Invest Ophthalmol Vis Sci 43:U875
Deng JS et al (2003) In vitro characterization of polyorthoester microparticles containing bupivacaine. Pharm Dev Technol 8(1):31–38
Molpeceres J et al (1999) A polycaprolactone nanoparticle formulation of cyclosporin-a improves the prediction of area under the curve using a limited sampling strategy. Int J Pharm 187(1):101–113
Sommerfeld P, Sabel BA, Schroeder U (2000) Long-term stability of PBCA nanoparticle suspensions. J Microencapsul 17(1):69–79
Gao JM et al (1998) Surface modification of polyanhydride microspheres. J Pharm Sci 87(2):246–248
Huang G et al (2004) Controlled drug release from hydrogel nanoparticle networks. J Control Release 94(2–3):303–311
Eastoe J, Warne B (1996) Nanoparticle and polymer synthesis in microemulsions. Curr Opin Colloid Interface Sci 1(6):800–805
Roy I et al (2003) Ceramic-based nanoparticles entrapping water-insoluble photosensitizing anticancer drugs: a novel drug-carrier system for photodynamic therapy. J Am Chem Soc 125(26):7860–7865
Morawski AM, Lanza GA, Wickline SA (2005) Targeted contrast agents for magnetic resonance imaging and ultrasound. Curr Opin Biotechnol 16(1):89–92
Bergen JM et al (2006) Gold nanoparticles as a versatile platform for optimizing physicochemical parameters for targeted drug delivery. Macromol Biosci 6(7):506–516
Kohler N et al (2005) Methotrexate-modified superparamagnetic nanoparticles and their intracellular uptake into human cancer cells. Langmuir 21(19):8858–8864
Loo C, Lowery A, Halas N, West J, Drezek R (2005) Immunotargeted nanoshells for integrated cancer imaging and therapy. Nano Lett 5(4):709–711
Hirsch LR et al (2003) Nanoshell-mediated near-infrared thermal therapy of tumors under magnetic resonance guidance. Proc Natl Acad Sci U S A 100(23):13549–13554
Tomalia DA et al (1985) A new class of polymers—starburst-dendritic macromolecules. Polym J 17(1):117–132
Longmire M, Choyke PL, Kobayashi H (2008) Clearance properties of nano-sized particles and molecules as imaging agents: considerations and caveats. Nanomedicine (Lond) 3(5):703–717
Bielinska A et al (1996) Regulation of in vitro gene expression using antisense oligonucleotides or antisense expression plasmids transfected using starburst PAMAM dendrimers. Nucleic Acids Res 24(11):2176–2182
Hong SP et al (2004) Interaction of poly(amidoamine) dendrimers with supported lipid bilayers and cells: hole formation and the relation to transport. Bioconjug Chem 15(4):774–782
Duncan R, Izzo L (2005) Dendrimer biocompatibility and toxicity. Adv Drug Deliv Rev 57(15):2215–2237
Khan MK et al (2005) In vivo biodistribution of dendrimers and dendrimer nanocomposites—implications for cancer imaging and therapy. Technol Cancer Res Treat 4(6):603–613
Lee CC et al (2005) Designing dendrimers for biological applications. Nat Biotechnol 23(12):1517–1526
Gillies ER, Frechet JMJ (2005) Dendrimers and dendritic polymers in drug delivery. Drug Discov Today 10(1):35–43
Malik N et al (2000) Dendrimers: relationship between structure and biocompatibility in vitro, and preliminary studies on the biodistribution of I-125-labelled polyamidoamine dendrimers in vivo. J Control Release 65(1–2):133–148
Maeda H (2001) SMANCS and polymer-conjugated macromolecular drugs: advantages in cancer chemotherapy. Adv Drug Deliv Rev 46(1):169–185
Petersen WC Jr et al (2014) Comparison of allergic reactions to intravenous and intramuscular pegaspargase in children with acute lymphoblastic leukemia. Pediatr Hematol Oncol 31(4):311–317
Duncan R (2014) Polymer therapeutics: top 10 selling pharmaceuticals—what next? J Control Release 190:371–380
Markovsky E et al (2012) Administration, distribution, metabolism and elimination of polymer therapeutics. J Control Release 161(2):446–460
Pisal DS, Kosloski MP, Balu-Iyer SV (2010) Delivery of therapeutic proteins. J Pharm Sci 99(6):2557–2575
Hays JL et al (2013) A phase II clinical trial of polyethylene glycol-conjugated l-asparaginase in patients with advanced ovarian cancer: early closure for safety. Mol Clin Oncol 1(3):565–569
Zhang R et al (2016) N-(2-hydroxypropyl)methacrylamide copolymer-drug conjugates for combination chemotherapy of acute myeloid leukemia. Macromol Biosci 16(1):121–128
Duncan R et al (1987) Anticancer agents coupled to N-(2-hydroxypropyl)methacrylamide copolymers: I. Evaluation of daunomycin and puromycin conjugates in vitro. Br J Cancer 55(2):165–174
Satchi-Fainaro R et al (2004) Targeting angiogenesis with a conjugate of HPMA copolymer and TNP-470. Nat Med 10(3):255–261
Seymour LW et al (2009) Phase II studies of polymer-doxorubicin (PK1, FCE28068) in the treatment of breast, lung and colorectal cancer. Int J Oncol 34(6):1629–1636
Chipman SD et al (2006) Biological and clinical characterization of paclitaxel poliglumex (PPX, CT-2103), a macromolecular polymer-drug conjugate. Int J Nanomedicine 1(4):375–383
Galic VL et al (2011) Paclitaxel poliglumex for ovarian cancer. Expert Opin Investig Drugs 20(6):813–821
O'Brien ME et al (2008) Randomized phase III trial comparing single-agent paclitaxel Poliglumex (CT-2103, PPX) with single-agent gemcitabine or vinorelbine for the treatment of PS 2 patients with chemotherapy-naive advanced non-small cell lung cancer. J Thorac Oncol 3(7):728–734
Patel LN, Zaro JL, Shen WC (2007) Cell penetrating peptides: intracellular pathways and pharmaceutical perspectives. Pharm Res 24(11):1977–1992
Lindgren M et al (2000) Cell-penetrating peptides. Trends Pharmacol Sci 21(3):99–103
Li ZJ, Cho CH (2012) Peptides as targeting probes against tumor vasculature for diagnosis and drug delivery. J Transl Med 10(Suppl 1):S1
Zhao Y et al (2014) CD44-tropic polymeric nanocarrier for breast cancer targeted rapamycin chemotherapy. Nanomedicine (Lond) 10(6):1221–1230
Journo-Gershfeld G et al (2012) Hyaluronan oligomers-HPMA copolymer conjugates for targeting paclitaxel to CD44-overexpressing ovarian carcinoma. Pharm Res 29(4):1121–1133
Bonnet ME et al (2013) Systemic delivery of sticky siRNAs targeting the cell cycle for lung tumor metastasis inhibition. J Control Release 170(2):183–190
Shen J et al (2013) Simultaneous inhibition of metastasis and growth of breast cancer by co-delivery of twist shRNA and paclitaxel using pluronic P85-PEI/TPGS complex nanoparticles. Biomaterials 34(5):1581–1590
Rajeev KG et al (2015) Hepatocyte-specific delivery of siRNAs conjugated to novel non-nucleosidic trivalent N-acetylgalactosamine elicits robust gene silencing in vivo. Chembiochem 16(6):903–908
Sehgal D, Vijay IK (1994) A method for the high efficiency of water-soluble carbodiimide-mediated amidation. Anal Biochem 218(1):87–91
Majoros IJ et al (2006) PAMAM dendrimer-based multifunctional conjugate for cancer therapy: synthesis, characterization, and functionality. Biomacromolecules 7(2):572–579
Majoros IJ et al (2005) Poly(amidoamine) dendrimer-based multifunctional engineered nanodevice for cancer therapy. J Med Chem 48(19):5892–5899
Klibanov AL, Torchilin VP, Zalipsky S (2003) Chemical conjugation. In: Torchilin VP, Weissig V (eds) Liposomes: practical approach. Oxford University Press, Oxford, pp 193–265
Gupta B et al (2005) Monoclonal antibody 2C5-mediated binding of liposomes to brain tumor cells in vitro and in subcutaneous tumor model in vivo. J Drug Target 13(6):337–343
Spragg DD et al (1997) Immunotargeting of liposomes to activated vascular endothelial cells: a strategy for site-selective delivery in the cardiovascular system. Proc Natl Acad Sci U S A 94(16):8795–8800
Prabhakar U et al (2013) Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology. Cancer Res 73(8):2412–2417
Yhee JY et al (2013) Tumor-targeting transferrin nanoparticles for systemic polymerized siRNA delivery in tumor-bearing mice. Bioconjug Chem 24(11):1850–1860
Park HK et al (2015) Smart nanoparticles based on hyaluronic acid for redox-responsive and CD44 receptor-mediated targeting of tumor. Nanoscale Res Lett 10(1):981
Rashidi LH et al (2015) Investigation of the strategies for targeting of the afterglow nanoparticles to tumor cells. Photodiagnosis Photodyn Ther 2015. doi:10.1016/j.pdpdt.2015.08.001
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Controlled Release Society
About this chapter
Cite this chapter
Landesman-Milo, D., Qassem, S., Peer, D. (2016). Targeting Cancer Using Nanocarriers. In: Howard, K., Vorup-Jensen, T., Peer, D. (eds) Nanomedicine. Advances in Delivery Science and Technology. Springer, New York, NY. https://doi.org/10.1007/978-1-4939-3634-2_7
Download citation
DOI: https://doi.org/10.1007/978-1-4939-3634-2_7
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4939-3632-8
Online ISBN: 978-1-4939-3634-2
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)